Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Regulus Therapeutics Inc (NASDAQ:RGLS)

1.05
Delayed Data
As of Jun 27
 +0.03 / +2.94%
Today’s Change
0.86
Today|||52-Week Range
5.35
-53.33%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$54.2M

Company Description

Regulus Therapeutics, Inc. engages in the discovery and development of drugs targeting microRNAs. It is developing RG-101, which targets miR-122, a host factor for the hepatitis C virus infection. The company was founded in September 2007 and is headquartered in San Diego, CA.

Contact Information

Regulus Therapeutics, Inc.
10614 Science Center Drive
San Diego California 92121
P:(858) 202-6300
Investor Relations:

Employees

Shareholders

Individual stakeholders36.52%
Other institutional27.37%
Mutual fund holders24.98%

Top Executives

Joseph P. HaganPresident, CEO, COO & Director
Daniel R. ChevallardChief Financial & Accounting Officer
Timothy M. WrightChief Research & Development Officer
Mark DeegChief Medical Officer
Michael HuangVice President-Clinical Development